Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea Prefilled Syringe Usability Study
NCT03767738Phase 4Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Aug 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), diabetic retinopathy (DR), sponsored by Regeneron Pharmaceuticals. Started Dec 2018; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)retinal vein occlusion (RVO)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03767738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767738.